Vertex Pharmaceuticals (VRTX) Current Deferred Revenue (2009 - 2017)
Vertex Pharmaceuticals (VRTX) posted quarterly Current Deferred Revenue of $5.2 million for Q4 2017, down 13.92% year-over-year from $6.0 million in Q4 2016, and down 60.25% quarter-over-quarter from $13.0 million in Q3 2017.
Vertex Pharmaceuticals (VRTX) Current Deferred Revenue (2009 - 2017) Analysis & Trends
Vertex Pharmaceuticals' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $5.2 million for Q4 2017.
- In Q4 2017, Current Deferred Revenue fell 13.92% year-over-year to $5.2 million; the TTM figure through Dec 2017 stood at $5.2 million (down 13.92% YoY), while the FY2017 annual figure was $5.2 million, down 13.92% from the prior year.
- Current Deferred Revenue for Q4 2017 stood at $5.2 million, down from $13.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $35.5 million in Q1 2013, with the low at $5.2 million in Q4 2017.
- The 5-year median for Current Deferred Revenue is $15.4 million (2015), against an average of $17.5 million.
- The sharpest annual moves came in 2016 and 2017: Current Deferred Revenue sank 63.15% in 2016, then soared 40.62% in 2017.
- Vertex Pharmaceuticals' Current Deferred Revenue stood at $21.5 million in 2013, then slipped by 18.79% to $17.5 million in 2014, then decreased by 6.71% to $16.3 million in 2015, then tumbled by 63.15% to $6.0 million in 2016, then retreated by 13.92% to $5.2 million in 2017.
- Business Quant data shows VRTX's Current Deferred Revenue at $5.2 million in Q4 2017, $13.0 million in Q3 2017, and $7.3 million in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 5.17 Mn |
| Sep 30, 2017 | 13.00 Mn |
| Jun 30, 2017 | 7.28 Mn |
| Mar 31, 2017 | 6.06 Mn |
| Dec 31, 2016 | 6.01 Mn |
| Sep 30, 2016 | 9.25 Mn |
| Jun 30, 2016 | 11.47 Mn |
| Mar 31, 2016 | 14.71 Mn |
| Dec 31, 2015 | 16.30 Mn |
| Sep 30, 2015 | 14.00 Mn |
| Jun 30, 2015 | 14.93 Mn |
| Mar 31, 2015 | 15.92 Mn |
| Dec 31, 2014 | 17.47 Mn |
| Sep 30, 2014 | 21.21 Mn |
| Jun 30, 2014 | 27.17 Mn |
| Mar 31, 2014 | 28.84 Mn |
| Dec 31, 2013 | 21.51 Mn |
| Sep 30, 2013 | 31.01 Mn |
| Jun 30, 2013 | 32.90 Mn |
| Mar 31, 2013 | 35.53 Mn |